title: Anti-inflammatory drugs reduce the risk of hepatocellular carcinoma development.
abstract: Nowadays, patients with chronic hepatitis C in all countries are generally treated with interferon (IFN), and more than 50% of patients become HCV-RNA negative following PEG-IFN plus ribavirin therapy, but unfortunately, the IFN therapy is not effective in about 70% of patients with HCV-associated LC. In Japan, HCC actually develops in about 7% of those patients every year. A strategy for preventing HCC development other than IFN therapy is, therefore, urgently needed for those patients. We reported that the recurrence rate and the development of HCC was more rapid in the high serum ALT level (>80 IU) patients with HCV-associated LC. Sho-saiko-to, Juzen-taiho-to, and stronger-neo minophagen C are herbal medicines used in Japan to treat chronic viral liver diseases, and they work by reducing inflammatory processes and controlling ALT levels. Aggressive reduction therapy for ALT levels in HCV-LC patients could significantly prevent HCC development.
authors.affiliation: Department of Surgery, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Rino
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tarao
references.citation: Anticancer Res. 2006 May-Jun;26(3B):2221-6
references.pmid: 16821591
references.citation: Nucleic Acids Res. 1984 Feb 24;12(4):2137-45
references.pmid: 6701097
references.citation: Intern Med. 2010;49(7):633-6
references.pmid: 20371951
references.citation: Scand J Gastroenterol. 2009;44(11):1340-8
references.pmid: 19891585
references.citation: Int J Cancer. 2008 Dec 1;123(11):2503-11
references.pmid: 18785209
references.citation: Cancer. 1997 Feb 15;79(4):688-94
references.pmid: 9024706
references.citation: Cancer. 2002 Mar 15;94(6):1787-95
references.pmid: 11920542
references.citation: J Natl Cancer Inst. 1973 Nov;51(5):1723-5
references.pmid: 4762943
references.citation: Gut. 1990 Jul;31(7):800-6
references.pmid: 2370015
references.citation: Cancer. 1973 Feb;31(2):468-73
references.pmid: 4347190
references.citation: Gastroenterol Jpn. 1989 Dec;24(6):715-9
references.pmid: 2691317
references.citation: Dis Colon Rectum. 2005 Apr;48(4):775-86
references.pmid: 15747078
references.citation: Intervirology. 2000;43(1):20-6
references.pmid: 10773734
references.citation: Cancer Sci. 2003 Dec;94(12):1083-90
references.pmid: 14662024
references.citation: Ann Intern Med. 2000 Apr 4;132(7):517-24
references.pmid: 10744587
references.citation: J Hepatol. 1993 Nov;19(3):459-64
references.pmid: 8151107
references.citation: Cancer. 1999 Aug 15;86(4):589-95
references.pmid: 10440686
references.citation: Hepatology. 1999 Apr;29(4):1124-30
references.pmid: 10094956
references.citation: Nature. 1991 Jan 31;349(6308):431-4
references.pmid: 1992344
references.citation: Hepatology. 2002 May;35(5):1125-33
references.pmid: 11981762
references.citation: Cancer Res. 1994 Jan 15;54(2):448-54
references.pmid: 8275481
references.citation: Cancer Res. 1994 Jun 15;54(12):3171-2
references.pmid: 8205535
references.citation: Oncology. 2002;62 Suppl 1:24-8
references.pmid: 11868781
references.citation: Cancer Res. 1997 Apr 1;57(7):1281-7
references.pmid: 9102214